Kevin M. Fain

United States Food and Drug Administration

Also affiliated with Center for Drug Evaluation and Research

Decision SciencesMedicineEconomics, Econometrics and Finance

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Race and ethnicity reporting for clinical trials in ClinicalTrials.gov and publications”.

Race and ethnicity reporting for clinical trials in ClinicalTrials.gov and publications

Contemporary Clinical Trials(2020)10.1016/j.cct.2020.106237

N/A

0.648DataRank · unranked

74 citations

Julianne Nelson, Tony Tse, Rebecca Williams, Kevin M. Fain

Potential benefits and burdens of National Institutes of Health and National Institute of Mental Health clinical trial policies

Contemporary Clinical Trials(2021)10.1016/j.cct.2021.106328

N/A

0DataRank · unranked

1 citations

Gail L. Daumit, Kevin M. Fain, Roberta W. Scherer, Emma E. McGinty, Eugene I. Kane

Evaluating the Revised National Institutes of Health clinical trial definition impact on recruitment progress

Research Evaluation(2022)10.1093/reseval/rvac003

N/A

0DataRank · unranked

3 citations

Gail L. Daumit, Kevin M. Fain, Roberta W. Scherer, Emma E. McGinty, Eugene I. Kane